Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice
/in International Publications, NSCLC /von 2008-06-01 / Cancer Biother. Radiopharm. 2008 Jun;23(3):321-31IFN-gamma down-regulates Hsp27 and enhances hyperthermia-induced tumor cell death in vitro and tumor suppression in vivo
/in International Publications, NSCLC /von 2008-06-01 / Int. J. Oncol. 2008 Jun;32(6):1317-24[Immunotherapy for glioma]
/in Glioblastoma, International Publications /von 2008-06-01 / Gan To Kagaku Ryoho 2008 Jun;35(6):926-30Radiotherapy with 8-MHz radiofrequency-capacitive regional hyperthermia for stage III non-small-cell lung cancer: the radiofrequency-output power correlates with the intraesophageal temperature and clinical outcomes
/in International Publications, NSCLC /von 2008-05-29 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):128-35Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef
/in HIV/AIDS, International Publications /von 2008-05-20 / Vaccine 2008 Jul;26(29-30):3735-41Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency
/in International Publications, Malignant Melanoma /von 2008-05-15 / Gene Ther. 2008 Oct;15(19):1321-9Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
/in Breast Cancer, International Publications /von 2008-05-15 / Cancer Res. 2008 May;68(10):3854-62
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de